| Ticker | KPTI |
|---|---|
| ISIN | US48576U2050 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adul...
Karyopharm Therapeutics Inc. opera en el sector Healthcare, industria Biotechnology.